HIV / AIDS in the News

HIV Stigma “Is Finally on the Decline,” GLAAD Reports - POZ

 

Gilead Hits Mark With Second Long-Acting HIV PrEP Trial - Scrip

 

HHS Proposes Rule to Increase Access to Kidney, Liver Transplants in HIV Patients - Medpage Today

 

CDC: U.S. Falls Short in Improving QoL for Older People With HIV - Medpage Today

 

Twice-a-Year HIV Injection Reduces Risk of Infection by 96% - RetailWire

 

Perimenopausal Women with HIV Experience Worse COVID-19 Symptoms - Managed Healthcare Executive

 

Twice-Yearly Lenacapavir for PrEP Reduced HIV Infections by 96% - Specialty Pharmacy Continuum

 

JD Vance now says Haitian immigrants are spreading HIV after bizarre pet-eating claim flops - Advocate.com

 

Fighting HIV Stigma: Empowering Global Leaders for Change - AJMC.com Managed Markets Network

 

Lenacapavir for PrEP Demonstrates Strong Efficacy in Second Phase 3 Trial - Drug Topics

 

Gilead’s biannual HIV shot reduced risk of infections by 96 percent, company says - The Independent

 

Gilead Stock Rises as HIV Prevention Injection Meets Study Goals - Yahoo Finance

 

Russians with HIV lose access to most commonly prescribed treatment - Новая газета. Европа

 

Helping End HIV - Gilead Sciences - CSRwire.com

 

HIV prevention leaders launch monthly webinars for updated Getting to Zero plan - Windy City Times

 

States weigh how to protect older adults from HIV-related discrimination in health care - Route Fifty

 

HIV Prevention enhancing public health awareness and resources - KNOP

 

HIV drug making large impact in the number of HIV cases - WXOW.com

 

Watch Highlights from Opening Day at USCHA 2024 - HIV.gov

 

Gilead Touts 96% HIV Risk Reduction With Twice-Yearly PrEP, Eyes Regulatory Filings - BioSpace

 

HIV supply airdrops in Kenya may save thousands of lives - LGBTQ Nation

 

Twice-yearly injection cuts HIV risk by 96%, but will cost cut access? - Medical Xpress

 

HIV-1 adapts to lost IP6 coordination through second-site mutations that restore conical capsid assembly - Nature.com

 

Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial - Yahoo Finance

 

JD Vance now says Haitian immigrants are spreading HIV after bizarre pet-eating claim flops - Yahoo! Voices

 

Gilead’s twice-yearly lenacapavir for HIV PrEP bests Truvada - The Pharma Letter

 

KFF Dashboard: Progress Toward Global HIV Targets in PEPFAR Countries - KFF

 

USCHA 2024 - Federal Update on HIV Programs & Syndemic Approach - HIV.gov

 

In a historic move, Colombia bypasses a patent to access a key HIV drug - Al Jazeera English

 

AIDS/LifeCycle to End in 2025 After 30 Years of Fundraising for HIV Services - The Pride LA